Skip to search formSkip to main contentSkip to account menu

IDN-6556

Known as: IDN 6556, IDN6556 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
This study examined the efficacy of the caspase inhibitor, IDN‐6556, in a rat model of liver ischemia‐reperfusion injury. Livers… 
2007
2007
In a mouse model of alpha-Fas-induced acute liver injury, the orally-administered caspase inhibitor PF-03491390 (formerly named… 
2006
2006
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Review
2005
Review
2005
Caspase inhibition has been demonstrated to be therapeutically effective in moderating excessive programmed cell death, or… 
Review
2004
Review
2004
The potency, efficacy and pharmacokinetic properties of IDN-6556, a first-in-class caspase inhibitor in clinical trials for the… 
Review
2004
Review
2004
IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by… 
Highly Cited
2003
Highly Cited
2003
OBJECTIVE To evaluate the safety of IDN-6556, a novel anti-apoptotic pan-caspase inhibitor, administered in single and multiple…